Because of its low toxicity, high specificity, low molecular weight and other unique advantages, it has become the best choice for patients. In addition, with the improvement of the manufacturing process and drug delivery systems, peptide drugs from the 70s of last century, Novartis Lypressin (lysine vasopressin) listed, has made rapid development.

According to the report of the global peptide therapy foundation shows that in the past few decades, the number of drugs into the clinical development of the increasing number of drugs, in 90s last year, an average of 9.7 kinds of 2000~2008, increased to.

During the period of 2000~2008, the most common indications for clinical studies of peptides were cancer and metabolic diseases (including diabetes and obesity), accounting for 18% and 17%, respectively. The study on the treatment of allergy, immune dysfunction and cardiovascular disease has decreased. According to the life sciences industry chief strategy and management consulting firm Bionest Partners estimates that the global peptide drugs market will grow from $5 billion 300 million in 2003 to $11 billion 500 million in 2013, a compound annual growth rate (CAGR) was 8.1%. In the global pharmaceutical market, a number of peptide drugs have been commercially successful, and its sales have reached or close to the level of blockbuster drug sales.

Upstart 1: acetic acid

Copaxone, Israel's leading pharmaceutical company, is a synthetic peptide preparation consisting of four amino acids, glutamic acid, alanine, tyrosine and lysine. Copaxone was approved by the U.S. FDA in 1996 for the treatment of multiple sclerosis. In western countries with multiple sclerosis, the efficacy and tolerability of Copaxone are highly positive.

At present, there is no domestic enterprises to apply for the replacement of Lei Lei or imports. 2011 Copaxone global sales reached $3 billion 600 million. It is reported that in the first quarter of this year, the drug hit $909 million in sales. In June, the company said it would bring $3 billion 800 million in revenue to the company this year, according to its annual economic forecast. But Copaxone's considerable gains have also led to the challenge of generics companies. Recently, Teva pharmaceutical company announced that the company had the same between Momenta biopharmaceutical company, Novartis Sandoz subsidiary, mailan pharmaceutical company and Natco biopharmaceutical company, several pharmaceutical companies patent Copaxone launched a lawsuit case, before the United States Court of New York said Teva pharmaceutical companies win. The company's exclusive marketing rights to the drug will be extended until 2014.

Upstart 2: acetic acid

Abbott's Lupron (acetic acid), is a naturally occurring gonadotropin releasing hormone (GnRH) or luteinizing hormone releasing hormone (LH-RH) synthesis of nine peptide analogs. Lupron broader indications, including endometriosis; associated with menorrhagia, abdominal pain, back pain and anemia of uterine fibroids; premenopausal breast cancer, estrogen receptor positive patients; prostate cancer; central precocious puberty.

2011, Abbott's Lupron global sales reached $810 million. In the Chinese market, Takeda Pharmaceutical Industry Co., Ltd. import sales since 2000. In 2009, Beijing boente Pharmaceutical Co. Ltd. and Shanghai Lizhu Pharmaceutical Company Limited listed domestic leuprolide. In recent years, the domestic 16 key city hospitals leuprolide administration of rapid growth, the growth rate remained at around 50%, in 2011 reached 57 million 300 thousand yuan. Domestic leuprolide market share, Takeda pharmaceutical industries occupy 86.73 of the market share.

Hot 3: goserelin acetate

AstraZeneca's Nored (goserelin acetate) is a luteinizing hormone releasing hormone injection analogues. Palliative care for advanced prostate cancer and the treatment of advanced breast cancer, endometriosis and uterine fibroids before and after menopause.

In 2011, AstraZeneca's global sales reached $1 billion 100 million in zoladex. In the China market, before the British Zeneca import sales from 1999, Astra company and Zeneca merged into AstraZeneca, sold by AstraZeneca to import. 2007~2011 years, the focus of 16 domestic city hospital sample acetate Gore Sherry Lin medication to maintain a rapid growth in 2010, although a slight slowdown, but the growth rate remained above 30%, in 2011 the national sample of hospitals in 16 key city Gore Sherry Lin drug is acetic acid reached 190 million yuan rmb.

Upstart 4: octreotide acetate

Novartis octreotide (octreotide acetate, eight) is a synthetic peptide derivative of natural somatostatin, it retains similar pharmacological effect and somatostatin, and the lasting effect. Octreotide acetate indications include Acromegaly; remission associated with functional gastrointestinal pancreatic endocrine tumor symptoms and signs; and of the carcinoid syndrome cancer tumor, VIP tumor, the expression of glucagon tumor effectively. In addition, octreotide acetate in gastrinoma /Zollinger-Ellison syndrome (usually associated with blocking agent and a proton pump inhibitor or H2 receptor), insulinoma (preoperative prevention of hypoglycemia and maintain normal blood glucose), the effective rate of growth hormone releasing factor of about 50%.

In 2011, Novartis Sandostatin's global sales of $1 billion 400 million. In the Chinese market, in 1999 by Novartis to import sales, in addition, India sun Pharmaceutical Co., Ltd. in 2009 began to import sales. Domestic products listed more than 20. 2011, 16 key cities in the sample of patients with acetic acid octreotide acetate reached 183 million yuan, of which half of the country accounted for Novartis, up to 52.77%.